Cardiol Therapeutics shares are trading lower. The company announced 8-week clinical data from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRx administered to patients with symptomatic recurrent pericarditis
Portfolio Pulse from Benzinga Newsdesk
Cardiol Therapeutics shares are trading lower following the announcement of 8-week clinical data from its Phase II MAvERIC-Pilot study on CardiolRx for symptomatic recurrent pericarditis.
June 13, 2024 | 4:24 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cardiol Therapeutics shares are trading lower after the company announced 8-week clinical data from its Phase II MAvERIC-Pilot study on CardiolRx for symptomatic recurrent pericarditis.
The release of clinical data often has a significant impact on biotech stocks. In this case, the market has reacted negatively to the 8-week data from the Phase II MAvERIC-Pilot study, causing a drop in Cardiol Therapeutics' share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100